

SUPPLEMENTAL MATERIALS

Supplemental Table I: ECG Intervals

	(R)-Propafenone			(S)-Propafenone			Placebo		
	Pre	Post	P-value*	Pre	Post	P-value*	Pre	Post	P-value*
RR interval (ms)	888 [746, 998]	1016 [851, 1095]	<0.001	863 [759, 970]	994 [860, 1094]	<0.001	839 [720, 1019]	980 [753, 1134]	0.001
PR interval (ms)	156 [141, 175]	163 [148, 183]	<0.001	159 [143, 180]	165 [151, 187]	0.002	141 [128, 163]	141 [129, 175]	0.344
QRS duration (ms)	96 [82, 106]	99 [89, 108]	<0.001	88 [78, 100]	96 [84, 108]	<0.001	90 [80, 105]	95 [86, 103]	0.048
QTc (ms)	421 [407, 454]	432 [408, 461]	0.154	430 [410, 454]	439 [413, 458]	0.012	425 [390, 448]	428 [402, 456]	0.920

*Paired comparison; Wilcoxon signed-rank tests of 20-min medians to Pre-drug medians

Supplemental Table II: Change in ECG Intervals (Pre/Post Study Drug)

	(R)-Propafenone	(S)-Propafenone	P-value (R) vs (S)*	Placebo	P-value (R) vs (S) vs Placebo†
Δ RR interval (ms)	107 [36, 202]	118 [18, 195]	0.998	102 [1, 221]	0.999
Δ PR interval (ms)	6 [-4, 17]	6 [-5, 17]	0.776	7 [-6, 10]	0.519
Δ QRS duration (ms)	5 [-3, 11]	5 [-1, 14]	0.400	3 [0, 12]	0.664
Δ QTc (ms)	2 [-10, 31]	10 [-12, 27]	0.998	-4 [-20, 26]	0.776

*Mann-Whitney U tests of differences in change between R and S-Propafenone.

†Kruskal-Wallis H test for three group variation.

Supplemental Table III: Measures of AV Nodal and Atrial Conduction and Refractoriness

	(R)-Propafenone (71)	(S)-Propafenone (75)	Placebo (19)	P-value*
AV Block Cycle Length (ms)	410 (70)	400 (75)	370 (18)	0.198
AV Node ERP @ 600 (ms)	310 (60)	295 (64)	290 (17)	0.878
AV Node ERP @ 450 (ms)	290 (54)	300 (60)	300 (17)	0.932
Atrial ERP @ 600 (ms)	240 (69)	240 (68)	250 (19)	0.990
Atrial ERP @ 450 (ms)	230 (63)	230 (68)	230 (18)	0.948

(Number of participants in parentheses). *P-value calculated using Kruskal-Wallis H test.

Supplemental Table IV: Arrhythmia Inducibility Endpoints

	Overall (N=165)	(R)- Propafenone (N=71)	(S)- Propafenone (N=75)	P-value (R) v. (S)*	Placebo (N=19)	P-value (R) v. (S) v. Placebo*
Sustained AF and/or AFL induced	132 (80.0%)	60 (84.5%)	60 (80.0%)	0.522	12 (63.2%)	0.118
Non-sustained AF and/or AFL induced	22 (29.3%)	18 (25.4%)	22 (29.3%)	0.711	5 (26.3%)	0.910
Stage induced (AF and/or AFL)				0.876		0.129
S1/S2	11 (6.7%)	5 (7.0%)	5 (6.7%)		1 (5.3%)	
15-beat burst	62 (37.6%)	28 (39.4%)	31 (41.3%)		3 (15.8%)	
15-second burst	59 (35.8%)	27 (38.0%)	24 (32.0%)		8 (42.1%)	
No AF and/or AFL induced	33 (20.0%)	11 (15.5%)	15 (20.0%)		7 (36.8%)	
Spontaneous termination of AF/AFL	70 (42.4%)	31 (43.7%)	30 (40.0%)	0.738	9 (47.4%)	0.813
Sustained AF-only induced (N=115)	82 (71.3%)	37 (77.1%)	34 (69.4%)	0.493	11 (61.1%)	0.384
Stage induced (AF-only)				0.979		0.403
S1/S2	9 (7.8%)	4 (8.3%)	4 (8.2%)		1 (5.6%)	
15-beat burst	27 (23.5%)	10 (20.8%)	14 (28.6%)		3 (16.7%)	
15-second burst	46 (40.0%)	23 (47.9%)	16 (32.6%)		7 (38.9%)	
No AF induced	33 (28.7%)	11 (22.9%)	15 (30.6%)		7 (38.9%)	
Sustained AFL-only induced	50 (30.3%)	23 (32.4%)	26 (34.7%)	0.861	1 (5.3%)	0.029

*P-values calculated using Fisher's exact test or Chi-square for trend.

Supplemental Figure I: Concentration of (*R*) and (*S*)-propafenone According to Treatment Assignment

